Lyell Immunopharma Announces Participation in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences:

• TD Cowen 46
  th
  Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern Time
• Leerink Annual Global Healthcare Conference on Monday, March 9, 2026, in Miami, Florida; fireside chat at 10:00am Eastern Time
• Citizens Life Science Conference on Tuesday, March 10, 2026, in Miami, Florida; fireside chat at 11:55am Eastern Time
  

A live webcast of each presentation can be accessed through the Investors section of the Company's website. Following each live presentation, a replay of the webcast will be available on the Company's website following the presentation date.

About Lyell

Lyell is a clinical stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness, and function in the hostile tumor microenvironment. Lyell’s LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit.

Forward-Looking Statements